Skip to content

Study · Randomized controlled trial · 2025

7 results

Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.

Beck J, Hasenböhler F, Werlen L, Lengsfeld S, Meienberg A, Bathelt C, Vogt D, Christ-Crain M, Burkard T, Winzeler B

European journal of preventive cardiology1 Oct 2025Cited by 2 (Europe PMC)

PMID40037282 (opens in a new tab)DOI10.1093/eurjpc/zwaf055 (opens in a new tab)PepBankPUB-40037282
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants undergoing smoking cessation, body weight in the dulaglutide arm decreased initially and then rebounded.

    In plain wordsIn participants stopping smoking, weight fell at first with dulaglutide and then rose again.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedBody weight over time
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · injection · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide treatment reduced body weight and blood pressure initially, followed by a weight rebound and a blood pressure increase of +7.5 mmHg (-1, 15) at Week 52.
    2 context sentences
    Summary · context
    This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Summary · context
    Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants undergoing smoking cessation, blood pressure in the dulaglutide arm decreased initially and then increased by +7.5 mmHg at Week 52.

    In plain wordsIn participants stopping smoking, blood pressure fell at first with dulaglutide and then rose by 7.5 mmHg at Week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedBlood pressure over time
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.5 mg weekly · injection · 12 weeksAs given in this study (human).

    Measurements

    Blood pressure change at Week 52, dulaglutide arm
    7.5 mmHg
    Week 52; interval (-1, 15) as reported

    Source sentences

    Summary
    Dulaglutide treatment reduced body weight and blood pressure initially, followed by a weight rebound and a blood pressure increase of +7.5 mmHg (-1, 15) at Week 52.
    2 context sentences
    Summary · context
    This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Summary · context
    Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks.

Studies that did not test the peptide alone5

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the pooled smoking-cessation population including placebo, systolic blood pressure remained stable over 52 weeks.

    In plain wordsIn the pooled smoking-cessation population including placebo, systolic blood pressure remained stable over 52 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePooled systolic blood pressure at week 52
    Study

    n = 218

    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    Across the entire study population, systolic blood pressure was stable over the period of 52 weeks after smoking cessation despite a weight gain of +3 kg (0, 5.4) at Week 52.
    3 context sentences
    Summary · context
    Two hundred and eighteen out of 255 participants with complete blood pressure readings were included in the analyses.
    Summary · context
    This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Summary · context
    Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the pooled smoking-cessation population including placebo, body weight increased by +3 kg at Week 52.

    In plain wordsIn the pooled smoking-cessation population including placebo, body weight increased by +3 kg at Week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePooled body weight at week 52
    Study

    n = 218

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Body weight change at Week 52, entire study population
    3 kg
    Week 52; interval (0, 5.4) as reported

    Source sentences

    Summary
    Across the entire study population, systolic blood pressure was stable over the period of 52 weeks after smoking cessation despite a weight gain of +3 kg (0, 5.4) at Week 52.
    3 context sentences
    Summary · context
    Two hundred and eighteen out of 255 participants with complete blood pressure readings were included in the analyses.
    Summary · context
    This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Summary · context
    Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther

    In the smoking-cessation path analysis, weight influenced systolic blood pressure changes without isolation of dulaglutide's effect.

    In plain wordsIn the smoking-cessation analysis, weight was linked to blood pressure changes without isolation of dulaglutide's effect.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableWeight association with blood pressure
    Study

    n = 218

    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    The path analysis identified weight as an important factor influencing blood pressure during smoking cessation.
    2 context sentences
    Summary · context
    This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Summary · context
    Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the pooled smoking-cessation subgroup with minimal weight gain, blood pressure decreased, without isolation of dulaglutide's effect.

    In plain wordsIn the pooled smoking-cessation subgroup with minimal weight gain, blood pressure decreased. This did not isolate dulaglutide's effect.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBlood pressure, minimal weight gain subgroup
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Blood pressure change, minimal weight gain subgroup
    −4.6 mmHg
    subgroup with weight gain <= 3 kg; interval (-9, 3) as reported

    Source sentences

    Summary
    Blood pressure reductions were seen in the subgroups of participants with minimal weight gain ≤3 kg [-4.6 mmHg (-9, 3)] and in individuals with hypertensive blood pressure values at baseline [-16 mmHg (-22, 2)].
    2 context sentences
    Summary · context
    This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Summary · context
    Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  5. 07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In the pooled smoking-cessation subgroup with baseline hypertension, blood pressure decreased, without isolation of dulaglutide's effect.

    In plain wordsIn the pooled smoking-cessation subgroup with baseline hypertension, blood pressure decreased. This did not isolate dulaglutide's effect.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBlood pressure, baseline hypertension subgroup
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Blood pressure change, baseline hypertension subgroup
    −16 mmHg
    participants with hypertensive baseline values; interval (-22, 2) as reported

    Source sentences

    Summary
    Blood pressure reductions were seen in the subgroups of participants with minimal weight gain ≤3 kg [-4.6 mmHg (-9, 3)] and in individuals with hypertensive blood pressure values at baseline [-16 mmHg (-22, 2)].
    2 context sentences
    Summary · context
    This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Summary · context
    Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT03204396

Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

University Hospital, Basel, Switzerlandn = 25626 Jun 2017 to 30 Aug 2022

Glucagon-like Peptide-1 · Smoking Cessation · Weight Change, Body · Craving

Trial pageClinicalTrials.govUpdated 13 Sept 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.